Rocket Pharmaceuticals (RCKT) closed at $2.39 on November 12, 2026, down 3.6% from the previous close, on volume of 925,193 shares (30-day average 1,893,954).
Data as of November 12, 2026.
12-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 12, 2026. See the 10 largest for 30, 60 and 90 days
Canaccord Genuity Reaffirms Their Buy Rating on Rocket Pharmaceuticals (RCKT)
TipRanks (Fri, 13-Nov 9:06 AM ET)
Rocket Pharmaceuticals (RCKT) Gets a Buy from Needham
TipRanks (Fri, 13-Nov 9:06 AM ET)
Rocket Pharmaceuticals (RCKT) Gets a Buy from Wedbush
TipRanks (Fri, 13-Nov 8:56 AM ET)
Rocket Pharmaceuticals GAAP EPS of -$0.43 misses by $0.03
Seeking Alpha News (Thu, 12-Nov 4:24 PM ET)
Rocket Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Recent Progress
Business Wire (Thu, 12-Nov 4:00 PM ET)
Cantor Fitzgerald Sticks to Its Buy Rating for Rocket Pharmaceuticals (RCKT)
TipRanks (Tue, 10-Nov 7:55 AM ET)
Rocket Pharmaceuticals to Participate in Chardan's 10th Annual Healthcare Conference
Business Wire (Thu, 15-Oct 7:00 AM ET)
Business Wire (Wed, 7-Oct 9:36 AM ET)
Business Wire (Tue, 6-Oct 4:12 PM ET)
Business Wire (Tue, 15-Sep 7:00 AM ET)
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.
Rocket Pharmaceuticals trades on the NASDAQ stock market under the symbol RCKT.
As of November 12, 2026, RCKT stock price declined to $2.39 with 925,193 million shares trading.
RCKT has a beta of 2.50, meaning it tends to be more sensitive to market movements. RCKT has a correlation of 0.17 to the broad based SPY ETF.
RCKT has a market cap of $262.36 million. This is considered a Small Cap stock.
Last quarter Rocket Pharmaceuticals reported $0 in Revenue and -$.37 earnings per share. This fell short of revenue expectation by $-13 million and missed earnings estimates by -$.71.
In the last 3 years, RCKT traded as high as $32.53 and as low as $2.17.
The top ETF exchange traded funds that RCKT belongs to (by Net Assets): VTI, IWM, VXF, FESM, IWN.
RCKT has underperformed the market in the last year with a price return of -27.6% while the SPY ETF gained +11.9%. RCKT has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -29.9% and -5.9%, respectively, while the SPY returned -1.7% and -1.6%, respectively.
RCKT support price is $2.36 and resistance is $2.60 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RCKT shares will trade within this expected range on the day.
